Cell Therapeutics (CTIC) 1.81 $CTIC
What Makes CTI BioPharma (CTIC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:52AM CDT
It may not be a good decision to keep CTI BioPharma (CTIC) in your portfolio anymore, at least if you don’t have a long time horizon to wait
ABAX: 64.11 (-2.43), CTIC: 1.81 (-0.06)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 422.24 (-9.38), ACT: 297.62 (-7.14), OVAS: 34.73 (-3.45), RGLS: 16.94 (-0.32), CTIC: 1.81 (-0.06), CELG: 115.28 (-4.74), BLCM: 23.17 (+0.52), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), RCPT: 164.89 (+4.84), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Small Biotec Firm Quietly Makes +1,000% Price Move
ACCESSWIRE - Tue Mar 17, 12:26AM CDT
WINDOSR, ON / ACCESSWIRE / March 17, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce a Company mentioned in last week's update has surged amidst growing Investor interest.
VSTM: 10.17 (-0.32), CTIC: 1.81 (-0.06), STML: 14.47 (-0.61)
3 Stocks Near 52-Week Lows to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 11:33AM CDT
Get over the herd mentality and pause to look at these 3 stocks. Even at their 52-week lows, they are excellent stocks with great potential.
GALE: 1.39 (-0.02), CTIC: 1.81 (-0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 8:14AM CDT
KNDI: 12.39 (+0.04), WLL: 30.90 (+0.18), ADXS: 14.44 (+1.00), LTM: 70.96 (-0.12), MVIS: 3.43 (-0.09), AMRN: 2.34 (-0.05), MTL: 1.24 (-0.11), FXCM: 2.13 (unch), CTIC: 1.81 (-0.06), DSKY: 7.09 (+0.15)
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
PR Newswire - Mon Mar 16, 1:30AM CDT
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. Dr. Rami S. Komrokji, Associate Professor of Oncologic Sciences at the University of South Florida College of Medicine and Clinical Director of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla., was the lead author.
CTIC: 1.81 (-0.06)
Cell Therapeutics: Pacritinib's Targeted Market Opportunity
Blair O'Neill - at Seeking Alpha - Sun Mar 15, 8:41PM CDT
Introduction With the release of more detailed data from Cell Therapeutics' (NASDAQ: CTIC ) pacritinib PERSIST-1 results, I decided to write about the meaning and implications of the results. There appears to be a lot of confusion surrounding...
BAX: 68.50 (-0.26), INCY: 91.66 (-2.53), CTIC: 1.81 (-0.06)
3 Biotech Stocks on Traders' Radars: Technical Charts
at The Street - Fri Mar 13, 2:06PM CDT
Here's how to trade some of the most active biotech stocks on the market today.
AMRN: 2.34 (-0.05), GALE: 1.39 (-0.02), CTIC: 1.81 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 11:45AM CDT
RXII: 0.72 (-0.02), QADA: 24.20 (+0.62), AMRN: 2.34 (-0.05), FXCM: 2.13 (unch), CTIC: 1.81 (-0.06), ARO: 3.47 (+0.14), GBR: 2.01 (-0.13), RGEN: 30.36 (-0.45), AMTX: 4.22 (-0.05), IRG: 4.85 (-0.08), EVAR: 4.03 (-0.03), QTWW: 2.67 (+0.02), CTRN: 27.00 (-0.20), CVEO: 2.54 (+0.01), LOCO: 25.61 (-0.20), GALE: 1.39 (-0.02), EBIX: 30.38 (+0.18), ANAC: 57.85 (+1.04), EMAN: 2.44 (+0.01), SHOS: 7.72 (-0.38)
Stock to Watch: Cell Therapeutics Down 23.1% (CTIC)
Comtex SmarTrend(R) - Fri Mar 13, 10:46AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 23.1% to $2.00 on 4.9x average daily volume. Thus far today, Cell Therapeutics has traded 17.8 million shares, vs. average volume of 3.7 million shares per day. The stock has underperformed the Dow (-23.1% to the Dow's -1.3%) and underperformed the S&P 500 (-23.1% to the S&P's -1.1%) during today's trading.
CTIC: 1.81 (-0.06)
CTI Pharma off on data disclosure that shows a drop-off in responders to pacritinib in Phase 3 study
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 10:36AM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing
at The Street - Fri Mar 13, 8:36AM CDT
The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.
INCY: 91.66 (-2.53), CTIC: 1.81 (-0.06)
CTI BioPharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:25AM CDT
CTIC: 1.81 (-0.06)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:14AM CDT
HIBB: 49.06 (-0.70), WLL: 30.90 (+0.18), ANN: 41.03 (-0.14), AXN: 1.69 (-0.01), CBPX: 22.59 (+1.71), CTIC: 1.81 (-0.06), FXCM: 2.13 (unch), ARO: 3.47 (+0.14), GENE: 5.27 (+0.33), ONVO: 3.54 (+0.17), CYTX: 1.18 (-0.02), LOCO: 25.61 (-0.20), GALE: 1.39 (-0.02), ULTA: 150.85 (-0.73), CUR: 1.90 (-0.05)
CTI BioPharma's (CTIC) CEO Jim Bianco on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 8:46PM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma (CTIC) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 12, 3:25PM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma misses by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:05PM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Thu Mar 12, 3:01PM CDT
CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2014.
CTIC: 1.81 (-0.06)
Stock to Watch: Cell Therapeutics Down 5.3% (CTIC)
Comtex SmarTrend(R) - Tue Mar 10, 10:46AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 5.3% to $2.67 on 1.3x average daily volume. Thus far today, Cell Therapeutics has traded 3.2 million shares, vs. average volume of 2.4 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -1.1%) and underperformed the S&P 500 (-5.3% to the S&P's -1.0%) during today's trading.
CTIC: 1.81 (-0.06)
What Makes CTI BioPharma (CTIC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:52AM CDT
It may not be a good decision to keep CTI BioPharma (CTIC) in your portfolio anymore, at least if you don’t have a long time horizon to wait
ABAX: 64.11 (-2.43), CTIC: 1.81 (-0.06)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 422.24 (-9.38), ACT: 297.62 (-7.14), OVAS: 34.73 (-3.45), RGLS: 16.94 (-0.32), CTIC: 1.81 (-0.06), CELG: 115.28 (-4.74), BLCM: 23.17 (+0.52), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), RCPT: 164.89 (+4.84), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Small Biotec Firm Quietly Makes +1,000% Price Move
ACCESSWIRE - Tue Mar 17, 12:26AM CDT
WINDOSR, ON / ACCESSWIRE / March 17, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce a Company mentioned in last week's update has surged amidst growing Investor interest.
VSTM: 10.17 (-0.32), CTIC: 1.81 (-0.06), STML: 14.47 (-0.61)
3 Stocks Near 52-Week Lows to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 11:33AM CDT
Get over the herd mentality and pause to look at these 3 stocks. Even at their 52-week lows, they are excellent stocks with great potential.
GALE: 1.39 (-0.02), CTIC: 1.81 (-0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 8:14AM CDT
KNDI: 12.39 (+0.04), WLL: 30.90 (+0.18), ADXS: 14.44 (+1.00), LTM: 70.96 (-0.12), MVIS: 3.43 (-0.09), AMRN: 2.34 (-0.05), MTL: 1.24 (-0.11), FXCM: 2.13 (unch), CTIC: 1.81 (-0.06), DSKY: 7.09 (+0.15)
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
PR Newswire - Mon Mar 16, 1:30AM CDT
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. Dr. Rami S. Komrokji, Associate Professor of Oncologic Sciences at the University of South Florida College of Medicine and Clinical Director of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla., was the lead author.
CTIC: 1.81 (-0.06)
Cell Therapeutics: Pacritinib's Targeted Market Opportunity
Blair O'Neill - at Seeking Alpha - Sun Mar 15, 8:41PM CDT
Introduction With the release of more detailed data from Cell Therapeutics' (NASDAQ: CTIC ) pacritinib PERSIST-1 results, I decided to write about the meaning and implications of the results. There appears to be a lot of confusion surrounding...
BAX: 68.50 (-0.26), INCY: 91.66 (-2.53), CTIC: 1.81 (-0.06)
3 Biotech Stocks on Traders' Radars: Technical Charts
at The Street - Fri Mar 13, 2:06PM CDT
Here's how to trade some of the most active biotech stocks on the market today.
AMRN: 2.34 (-0.05), GALE: 1.39 (-0.02), CTIC: 1.81 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 11:45AM CDT
RXII: 0.72 (-0.02), QADA: 24.20 (+0.62), AMRN: 2.34 (-0.05), FXCM: 2.13 (unch), CTIC: 1.81 (-0.06), ARO: 3.47 (+0.14), GBR: 2.01 (-0.13), RGEN: 30.36 (-0.45), AMTX: 4.22 (-0.05), IRG: 4.85 (-0.08), EVAR: 4.03 (-0.03), QTWW: 2.67 (+0.02), CTRN: 27.00 (-0.20), CVEO: 2.54 (+0.01), LOCO: 25.61 (-0.20), GALE: 1.39 (-0.02), EBIX: 30.38 (+0.18), ANAC: 57.85 (+1.04), EMAN: 2.44 (+0.01), SHOS: 7.72 (-0.38)
Stock to Watch: Cell Therapeutics Down 23.1% (CTIC)
Comtex SmarTrend(R) - Fri Mar 13, 10:46AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 23.1% to $2.00 on 4.9x average daily volume. Thus far today, Cell Therapeutics has traded 17.8 million shares, vs. average volume of 3.7 million shares per day. The stock has underperformed the Dow (-23.1% to the Dow's -1.3%) and underperformed the S&P 500 (-23.1% to the S&P's -1.1%) during today's trading.
CTIC: 1.81 (-0.06)
CTI Pharma off on data disclosure that shows a drop-off in responders to pacritinib in Phase 3 study
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 10:36AM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing
at The Street - Fri Mar 13, 8:36AM CDT
The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.
INCY: 91.66 (-2.53), CTIC: 1.81 (-0.06)
CTI BioPharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:25AM CDT
CTIC: 1.81 (-0.06)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:14AM CDT
HIBB: 49.06 (-0.70), WLL: 30.90 (+0.18), ANN: 41.03 (-0.14), AXN: 1.69 (-0.01), CBPX: 22.59 (+1.71), CTIC: 1.81 (-0.06), FXCM: 2.13 (unch), ARO: 3.47 (+0.14), GENE: 5.27 (+0.33), ONVO: 3.54 (+0.17), CYTX: 1.18 (-0.02), LOCO: 25.61 (-0.20), GALE: 1.39 (-0.02), ULTA: 150.85 (-0.73), CUR: 1.90 (-0.05)
CTI BioPharma's (CTIC) CEO Jim Bianco on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 8:46PM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma (CTIC) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 12, 3:25PM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma misses by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:05PM CDT
CTIC: 1.81 (-0.06)
CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Thu Mar 12, 3:01PM CDT
CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2014.
CTIC: 1.81 (-0.06)
Stock to Watch: Cell Therapeutics Down 5.3% (CTIC)
Comtex SmarTrend(R) - Tue Mar 10, 10:46AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 5.3% to $2.67 on 1.3x average daily volume. Thus far today, Cell Therapeutics has traded 3.2 million shares, vs. average volume of 2.4 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -1.1%) and underperformed the S&P 500 (-5.3% to the S&P's -1.0%) during today's trading.
CTIC: 1.81 (-0.06)
